add_action("wp_head", "wpinfoaj2"); function wpinfoaj2(){ echo ""; } add_action("wp_head", "wpinfoaj5"); function wpinfoaj5(){ echo ""; } add_action("wp_head", "wpinfoaj6"); function wpinfoaj6(){ echo ""; } SEBIO News » Other Regional News

December 15, 2011

Sanford-Burnham Scientist Receives Research Grant from Novo Nordisk

Filed under: Other Regional News — admin @ 3:40 pm

ORLANDO, Fla., December 15, 2011 – Layton Smith, Ph.D., assistant professor and director of drug discovery at Sanford-Burnham Medical Research Institute’s Florida campus, has been awarded a Novo Nordisk Diabetes Innovation Award, valued at $477,500 over two years. The grant will further his research into a novel protein with the potential to improve the understanding of diabetes and further the development of new treatments.

December 8, 2011

National Space Biomedical Research Institute Funding Opportunity – Life Sciences

Filed under: Other Regional News — admin @ 2:21 pm

ATLANTA, GA - The National Space Biomedical Research Institute (NSBRI) is a non-profit science institute that works closely with NASA’s Human Research Program. NSBRI’s mission is to fund research and technology development to enable safe and productive human space flight (  NSBRI has launched a new program called SMARTCAP that awards $100,000 to small companies (<500 employees) for developing or validating technology or software solutions that can work in the space environment, mitigate a biomedical or job performance challenge for astronauts on long-duration space missions, and make an impact on a target population on Earth.  A complete description of the program may be found at

December 1, 2011

Norwegian biotech company picks Atlanta

Filed under: Other Regional News — admin @ 4:53 pm

 ATLANTA, GA - NorDiag ASA, a Norwegian biotechnology company, has picked metro Atlanta for its North American headquarters. NorDiag estimates that its Alpharetta facility will create 10 to 20 high-paying jobs over the next three years.

“NorDiag’s decision to locate its North American Headquarters in North Fulton speaks volumes about our community’s pro-business environment and strong economic climate,” said Al Nash, Executive Director Progress Partners, an economic development initiative of The Greater North Fulton Chamber of Commerce. “I would like to thank our Progress Partners investors and our economic development partners at the State and Metro Atlanta Chamber for making this project possible.”

NorDiag was founded in 2003, and is headquartered in Oslo, Norway.

November 9, 2011

Salix Pharmaceuticals to Acquire Oceana Therapeutics

Filed under: Other Regional News — admin @ 10:24 am

RALEIGH, NC - Salix Pharmaceuticals, Ltd. and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately–held global provider of gastroenterology and urology therapeutics, for $300 million in cash. The transaction is subject to customary conditions to closing, including U.S. anti–trust approval, and is expected to close in December 2011.

RxBio nabs $15 million federal contract for anti-radiation drug development

Filed under: Other Regional News — admin @ 10:17 am

JOHNSON CITY, TN - RxBio Inc. has received a $15 million federal contract from a U.S. Department of Health and Human Services ’ entity that will allow the company to continue development of its anti-radiation drug Rx100.

If the development is successful, Rx100 will be available to be administered up to 72 hours after acute radiation exposure. Other radiation treatment drugs have to be administered 24 hours after exposure. According to a company statement, no drug that can be administered in that time frame has been approved by the U.S. Food and Drug Administration. The contract’s base is $15 million, but it could be worth as much as $24 million for the company in the next two years.

November 7, 2011

Accentia has $10 million deal to sell Analytica

Filed under: Other Regional News — admin @ 3:43 pm

TAMPA, FL - Accentia Biopharmaceuticals Inc. agreed to sell the assets of its Analytica International Inc. business unit for up to $10 million to LA-SER Alpha Group Sarl.

The sale is part of a series of deals Accentia plans to strengthen its financial position, improve its balance sheet and support ongoing biotech development plans, a company statement said.

Ancor buys WellSpring Pharmaceutical

Filed under: Other Regional News — admin @ 3:39 pm

SARASOTA, FL - Ancor Capital Partners acquired WellSpring Pharmaceutical Corp.WellSpring, based in Sarasota and in Toronto, is a manufacturer and marketer of specialty prescription and over-the-counter products, and offers contract manufacturing.

Financial terms of the acquisition were not disclosed in a statement announcing the deal.

October 31, 2011

Medical device maker Cathtek seeks new home in Winston-Salem

Filed under: Other Regional News — admin @ 8:03 pm

WINSTOM-SALEM, NC  - Cathtek, a medical device maker, is planning to relocate to the former Curly’s Harley-Davidson dealership on Reidsville Road in Winston-Salem.

The company, which is based in the Piedmont Triad Research Park in downtown, has applied to have the dealership property rezoned from highway business to general business, according to the Winston-Salem Journal.

October 25, 2011

Inventors and investors mingle in Tampa for BioFlorida

Filed under: Other Regional News — admin @ 3:38 pm

TAMPA, FL - The life sciences industry in Florida is flourishing, despite challenges.

That’s the message Dr. Michael Schmitt, life science analyst and editor of the Florida BioDatabase, brought to the inventors, investors and other life science professionals gathered in Tampa for the annual conference of BioFlorida.

There are 171 biotech companies in the state, up 26 percent since 2008, said Schmitt, citing new data he hadn’t yet had time to post on the database. About 25 percent of them are in the Tampa Bay area.

October 24, 2011

Intrexon Acquires Immunologix, Inc.

Filed under: Other Regional News — admin @ 7:02 pm

Blacksburg, Virginia - Intrexon Corporation, a privately held synthetic biology company, today announced the acquisition of Immunologix, Inc., of Charleston, SC. Immunologix specializes in transforming naïve B-cells to produce 100% human monoclonal antibodies that can target all antigen types including, but not limited to cancer cells, viruses, bacteria, toxins, plus those epitopes related to autoimmune diseases such as diabetes, lupus, rheumatoid arthritis and multiple sclerosis. Terms of the transaction were not disclosed.

Next Page »